David Walde

7.7k citations
24 papers · 6.1k · 2 hit papers · h-index 19

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology
    • HER2/EGFR in Cancer Research
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

    • Lung Cancer Research Studies 3
    • Pancreatic and Hepatic Oncology Research 3
    • Cancer Treatment and Pharmacology 3
    • Breast Cancer Treatment Studies 3

David Walde

24 papers receiving 5.8k citations

David Walde's Hit Papers

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group 2007 · 3.1k citations
3.1k0+8+16Years since publication10002.0k3.0k

Peers

David Walde
Comparison fields: 5 of 121
  • Oncology 4.0k
  • Cancer Research 1.2k
  • Pulmonary and Respiratory Medicine 1.1k
  • Hepatology 191
  • Surgery 693
Replace John Turner Hamm with:
John Turner Hamm United States
Thomas E. Seay United States
Scot D. Dowden Canada
Mark F. Kozloff United States
Markus Borner Switzerland
Connie Stephens United States
Giacomo Cartenì Italy
Pascal Artru France
Kenji Sugio Japan
Mark M. Zalupski United States
David Walde relative to John Turner Hamm United States John Turner Hamm's profile →
Citations per field
00.5×1.7×
John Turner Hamm · 1×
Citations per year

Countries citing papers authored by David Walde

Since Specialization
Citations

This map shows the geographic impact of David Walde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Walde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Walde more than expected).

Fields of papers citing papers by David Walde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Walde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Walde. The network helps show where David Walde may publish in the future.

Co-authors

The 25 scholars most cited alongside David Walde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Walde Line = papers co-authored together David Walde links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Hit paper breakdown →
20073124
2
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Hit paper breakdown →
2001954
3 2005775
4 2009197
5 2012180
6 1999103
7 199897
8 199788
9 200881
10 201174
11 200668
12 199759
13 201157
14 201049
15 201043
16 197142
17 199539
18
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
199535
19 202320
20 20078

About David Walde

David Walde is a scholar working on Oncology, Cancer Research, Surgery, Anesthesiology and Pain Medicine and Public Health, Environmental and Occupational Health, having authored 24 papers that have together received 6.1k indexed citations. Recurring topics across this work include Nausea and vomiting management (5 papers), Lung Cancer Research Studies (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Breast Cancer Treatment Studies (3 papers), Cancer Treatment and Pharmacology (3 papers), Estrogen and related hormone effects (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (4.0k citations), Cancer Research (1.2k citations), Pulmonary and Respiratory Medicine (1.1k citations), Hepatology (191 citations) and Surgery (693 citations). David Walde has collaborated with scholars based in Canada, United States and New Zealand. Frequent co-authors include Keyue Ding, Malcolm J. Moore, H. Au, P. Murawa, Gary M. Clark, Arié Figer, Robert A. Wolff, Robert S. C. Lim, David B Goldstein and Wendy R. Parulekar. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs, The Lancet Oncology and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact